1. Home
  2. NCSM vs ENGN Comparison

NCSM vs ENGN Comparison

Compare NCSM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCS Multistage Holdings Inc.

NCSM

NCS Multistage Holdings Inc.

N/A

Current Price

$49.83

Market Cap

135.6M

Sector

Energy

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.78

Market Cap

117.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCSM
ENGN
Founded
2006
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
135.6M
117.2M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
NCSM
ENGN
Price
$49.83
$1.78
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
5.3K
703.0K
Earning Date
04-29-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
239.22
56.85
EPS
N/A
N/A
Revenue
$142,471,000.00
N/A
Revenue This Year
$5.57
N/A
Revenue Next Year
$4.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.06
$1.40
52 Week High
$87.36
$12.25

Technical Indicators

Market Signals
Indicator
NCSM
ENGN
Relative Strength Index (RSI) 55.55 47.73
Support Level $42.69 $1.67
Resistance Level $51.69 $1.84
Average True Range (ATR) 1.26 0.07
MACD 0.11 0.01
Stochastic Oscillator 69.45 48.94

Price Performance

Historical Comparison
NCSM
ENGN

About NCSM NCS Multistage Holdings Inc.

NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: